louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03695536: The Impact of Integration of Ultrasound on CPR Quality - A Video Review Study
Official title: The Impact of Integration of Ultrasound on CPR Quality - A Video Review
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiopulmonary Resuscitation
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2018-10-04
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients (more than 20 years) with non-traumatic cardiac arrest at the emergency department of the National Taiwan University Hospital.

Brief summary: High-quality cardiopulmonary resuscitation (CPR) is essential for return of spontaneous circulation (ROSC) in patients with cardiac arrest. However, some factors are known to be related with delays in chest compressions such as bed transfer, setting of CPR device, pulse and rhythm checks. This study aims to evaluate the potential impact of ultrasound on CPR quality by using retrospective video analysis.

All CPR scenarios in our department were recorded and masked for the purpose of video analysis. The investigators will record in-scene resuscitation manpower, the factors to interrupt chest compressions and whether introducing ultrasound into resuscitation process is related with delays in chest compressions. In addition, the investigators collect the patient's sex, age, initial rhythm and prognosis, including ROSC, survival to admission and survival to discharge.


Eligibility criteria: Inclusion Criteria:

adult patients (more than 20 years) non-traumatic cardiac arrest

Exclusion Criteria:

traumatic cardiac arrest age less than 20 years.

Primary outcomes:
measure: Ultrasound use would not delay in chest compressions during resuscitation.
timeFrame: 60 minutes
Secondary outcomes:
measure: Ultrasound use would not influence the rates of return of spontaneous circulation.
timeFrame: 60 mintues
measure: Ultrasound use would not influence the rates of survival to admission.
timeFrame: 7 days.
measure: Ultrasound use would not influence the rates of survival to discharge.
timeFrame: 3 months.
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Department of Emergency Medicine, National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT03182036: Portable Oxygen Concentrator Signal Capture Study
Official title: Portable Oxygen Concentrator Signal Capture Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypoxia
Lead sponsor: ResMed
Sponsor class: INDUSTRY
Collaborators: name: St George Hospital, Australia
First posted: 2017-06-09
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to learn how patients breathe on portable oxygen concentrators (POCs), and to get feedback from patients using POCs.

Detailed description: This study aims to examine patient oxygenation levels and markers of exertion (e.g. breath rate, heart rate and breath pattern) while using a portable oxygen concentrator, with the aim to understand exercise desaturation in hypoxemic subjects.

Eligibility criteria: Inclusion Criteria:

* Patient is willing to give written informed consent
* Patient can read and comprehend English
* Patient is ≥ 18 years of age
* Patient has moderate to severe hypoxaemia (SpO2 ≤ 92%) at rest
* Patient reports shortness of breath on exertion

Exclusion Criteria:

* Patient has musculoskeletal impairment, or other impairment that may be the limiting factor in 6MWT
* Patient has a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study
* Patient has acute coronary syndrome, acute myo- or pericarditis, acute lung embolism, pulmonary infarction, acute uncontrolled heart insufficiency
* Patient shows signs of acute exacerbation of underlying lung condition
* Patient is deemed to be unsuitable for inclusion in the opinion of the researcher, including for the following reasons:
* they do not comprehend English
* they are unable to provide written informed consent
* they are physically unable to comply with the protocol

Primary outcomes:
measure: Oxygenation
timeFrame: 20 minutes
Secondary outcomes:
measure: Heart rate
timeFrame: 20 minutes
measure: Nasal cannula pressure
timeFrame: 20 minutes
Other outcomes:
Locations:
city: Kogarah
country: Australia
facility: St George Hospital
state: New South Wales
Study officials:
affiliation: ResMed
name: Paul A Dickens, PhD
role: STUDY_DIRECTOR
affiliation: ResMed
name: Peter Wlodarczyk, BEng
role: STUDY_DIRECTOR
References:
Clinical trial NCT01640236: Flare Measurements in Human Radiation Therapy Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: The Impact of Whole Body Irradiation on Ocular Flare
Keywords: Ocular flare
Lead sponsor: ChromoLogic, LLC
Sponsor class: INDUSTRY
Collaborators: name: University of California, Los Angeles
First posted: 2012-07-13
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients meeting the inclusion/exclusion criteria and receiving whole body irradiation at the UCLA Radiation Oncology clinic

Brief summary: This is a longitudinal Feasibility Study of a novel non-invasive device in assessing radiation dose exposure in humans. All patients receiving whole body irradiation therapy and meeting all other inclusion/exclusion criteria will receive ocular flare meter measurements and slit-lamp examinations on up to eleven occasions starting prior to the first fractional dose of irradiation.


Eligibility criteria: Inclusion Criteria:

* Subjects must be scheduled to receive whole body irradiation in a dose range from 1.5 to 12Gy.
* Subjects must not have received ocular surgery for at least three months prior to study enrolment.
* Subjects must not have a history of uveitis.
* Subjects must have at least one eye free of cataracts
* Subject age must be greater than 18 years
* Subjects must have the ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

* Inability to give informed consent
* Cataracts in both eyes
* Subject has received ocular surgery within the prior three months
* Subject has a history of uveitis

Primary outcomes:
measure: Ocular flare in radiotherapy patients
timeFrame: Daily measurements for the duration of radiotherapy treatment (expected up to four days from start of treatment)
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA Radiation Oncology
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Michell Kamrava, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03045536: Evaluation of Partial and Total Femoral Replacement
Official title: Evaluation of Partial and Total Femoral Replacement Treated in a Single Orthopedic Centre
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Survival, Prostheses
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2017-02-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators retrospectivel review our institution's database for patients who underwent resection of the partial or whole femur due to bone tumors or failed revision arthroplasties and reconstruction by TFR from January 1995 to January 2011.

Brief summary: Several surgical options for the reconstruction of massive bone defects have been described and include biologic methods with autografts and allografts, and the use of tumor endoprostheses (total femoral replacement, TFR). Several types of modular TFR are available, but nevertheless unpredictable outcomes and high complication rates have been described from most authors. The aim of the present study was to compare complication rates after TFR performed with modular total femur prosthesis MML (Fa. ESKA/Orthodynamics) in patients with and without malignant disease.


Eligibility criteria: Inclusion Criteria:

* Total or partial femoral replacement

Exclusion Criteria:

* Failure of device

Primary outcomes:
measure: Survival of device
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Klinikum rechts der Isar
Study officials:
affiliation: Klinikum rechts der Isar
name: norbert harrasser
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01356836: The Association Between Different Monocyte Subsets and Coronary Collateral Development
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Coronary Ischemia
Keywords: Coronary collateral development
monocyte subsets
collateralization
Lead sponsor: Yuksek Ihtisas Hospital
Sponsor class: OTHER
First posted: 2011-05-20
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients who were found to have \>95% stenosis of at least one major coronary artery in their first coronary angiogram were included in this study.

Brief summary: Collateral growth and coronary angiogenesis are chronic adaptations to myocardial ischemia. Collateralization helps to restore blood flow and as a result salvages myocardium in severely ischemic myocardial regions. Thus, good collateral development in patients with severe coronary artery disease (CAD) improves ventricular function and prognosis (1-3).

However, coronary collateral development is different among patients even with similar degrees of coronary artery stenosis. Several factors, such as diabetes mellitus (4) and duration of myocardial ischemic symptoms (5) have been reported to effect coronary collateral development. At the cellular level, inflammatory cells, especially monocytes have an important role in collateralization. In a series of experimental studies with animals, it has been shown that monocytes are important elements for development of collateral vessels (6-7). In a recent study, it has been demonstrated that increased circulating monocyte count is related to good collateral development in patients with stable coronary artery disease (8).

Monocytes in human blood are heterogeneous and can be classified into two subsets according to the presence or absence of the FcγRIII receptor CD16 (9): CD14++CD16- monocytes characterized by high level expression of the CD14 cell surface receptor but no expression of CD16 receptor, and CD14+CD16+ monocytes characterized by the co-expression of CD16 receptor with either high or low level expression of the CD14 receptor. These subsets differ in function and response to several cytokines.

Our aim in this study was to find out any possible relationship between the levels of circulating monocyte subsets and coronary collateral development.


Eligibility criteria: Inclusion Criteria:

* \> 95% stenosis of at least one major coronary artery in their first coronary angiogram

Exclusion Criteria:

* previous percutaneous or surgical revascularization history
* evidence of ongoing infection and inflammation
* known malignancy and chronic kidney disease (serum creatinine \> 1.5 mg/dl
* diabetic patients

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: 1Türkiye Yüksek İhtisas Education and Research Hospital, Department of Cardiology
Study officials:
References:
Clinical trial NCT02993536: Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab
Official title: Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Chronic Lymphocytic Leukemia
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2016-12-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with relapsed or refractory CLL requiring treatment and receiving idelalisib-rituximab

Brief summary: The purpose of the study is to assess the evolution of B cells at a genetic and surface-marker level in high-risk CLL after idelalisib-rituximab treatment. The targeted population includes 20 subjects ages 18 or older diagnosed with high-risk CLL. This will include patients with relapsed or refractory disease who require therapy with idelalisib and rituximab as per FDA label. This is an observational study for peripheral blood samples of these patients collected at pre-determined time points.


Eligibility criteria: Inclusion Criteria:

* Age over 18
* Ability to provide informed consent
* Ability to provide peripheral blood samples
* Diagnosis of CLL
* Indication(s) for CLL therapy
* At least one criterion for high-risk disease

  * Disease refractory (e.g., no response) to at least one round of chemotherapy
  * Disease that has relapsed (i.e., returned) after at least one round of chemotherapy
  * Proven presence of the 17p deletion within CLL cells
* Planned receipt of idelalisib-rituximab as per FDA guidelines and patient's oncologists

Exclusion Criteria:

* Patients who do not meet the diagnostic criteria for CLL or at least one indication for treatment.
* Patients who are receiving idelalisib with an off-label indication
* Patients who do not or cannot provide informed consent to donate peripheral blood tumor samples to our stem cell core facility
* Patients who do not provide informed consent to collect clinical, prognostic, and outcomes data during the time period that they are treated with idelalisib-rituximab

Primary outcomes:
measure: Number of somatic hypermutation
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Anthony Mato, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04682236: Study of the Evolution Profile of the Renal Doppler in the Perioperative Hepathic Transplantation
Official title: Study of the Evolution Profile of the Renal Doppler in the Perioperative Hepathic Transplantation - Interest in Predicting the Occurence of Acute Postoperative Renal Faillure
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Renal Failure
Keywords: Acute Renal Failure
Chronic renal failure
Liver transplant
Renal vascular profiles
Intraoperative hemodynamic instability
Acute tubular necrosis
Renal doppler
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2020-12-23
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient operated on at the HUS for a liver transplant, between July 1, 2019 and June 30, 2020

Brief summary: Liver transplantation is associated with a modification of the perfusion pressures of the abdominal organs (preoperative portal hypertension in connection with liver pathology, and normalization of the perfusion pressures during surgery). This abrupt change in the infusion regime is probably responsible for an alteration in renal function in some patients, and the identification of renal vascular profiles using Doppler could point to pathological profiles, which should be diagnosed early.


Eligibility criteria: Inclusion Criteria:

* Patient of full age (≥18 years)
* Patient operated on at the HUS for a liver transplant, between July 1, 2019 and June 30, 2020.
* Patients having undergone an evaluation of hepatic and renal vascular profiles perioperatively.
* Patients hospitalized in the surgical intensive care unit after hepatic transplant surgery.
* Patient not having expressed, after information, the reuse of his data for the purposes of this research

Exclusion Criteria:

* Patient who expressed his opposition to participating in the study
* Patient with suspected obstructive acute renal failure
* Stenosis of renal arteries known at the time
* End-stage renal disease on dialysis
* Impossibility of giving the subject informed information (difficulties in understanding the subject, etc.)
* Subject under safeguard of justice

Primary outcomes:
measure: Retrospective analysis of the development profiles of renal dopplers in perioperative liver transplantation
timeFrame: Files analysed retrospectily from July 1st, 2019 to June 30, 2020 will be examined
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Strasbourg University Hospitals - Anesthesia-intensive care unit
Study officials:
affiliation: Strasbourg University Hospitals - Anesthesia-intensive care unit
name: Julien POTTECHER, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01735136: Efficacy and Safety of InSan Bamboo Salt on Improvement of Helicobacter Pylori Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Helicobacter Pylori Infection
Lead sponsor: Chonbuk National University Hospital
Sponsor class: OTHER
First posted: 2012-11-28
Enrollment: 60
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators performed a 4-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of InSan Bamboo Salt on improvement of Helicobacter pylori infection. The investigators measured improvement of Helicobacter pylori infection parameters , including 14C-UBT(Urea breath test), and subjects' symptoms, and monitored their blood pressure.


Eligibility criteria: Inclusion Criteria:

* Males and females 19-65 years old
* 14C-UBT test ≥ 100 cpm
* Endoscopy results showing gastritis
* Able to give informed consent

Exclusion Criteria:

* Diagnosed of gastrointestinal disease such as ulcer, cancer, more than 10 erosions
* Taken antibiotics and stomach medicines such as steroid, bismuth compound, H2-receptor antagonist and proton pump inhibitor within 2 weeks
* Allergic or hypersensitive to any of the ingredients in the test products
* History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
* History of alcohol or substance abuse
* Participation in any other clinical trials within past 2 months
* Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
* Pregnant or lactating women etc.

Primary outcomes:
measure: Changes in 14C-UBT(Urea breath test)
timeFrame: 4 weeks
Secondary outcomes:
measure: Changes in subjects' symptoms
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
state: Jeollabuk-do
Study officials:
References:
Clinical trial NCT06133036: Fecal Continence Outcomes and Quality of Life After Excision of Sacrococcygeal Teratoma (Retrospective Study)
Official title: Fecal Continence Outcomes and Quality of Life After Excision of Sacrococcygeal Teratma (Retrospective Study)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sacrococcygeal Teratoma
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-11-15
Enrollment: 20
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients operated in Sohag university hospital after july 2010 for sacrococcygeal teratoma.

Brief summary: Sacrococcygeal teratoma is one of the most common tumors that occur in the neonatal period. It presents either as a mass protruding from the sacrococcygeal region or as a pelviabdominal mass according to the type. Surgical excision is the main treatment, most masses are benign, however some are malignant and require radiotherapy or chemotherapy. Complications may occur due to pressure resulting from the tumor growth in the fetal period, or due to damage to important near tissues during surgical excision. Postoperative complications may be urinary as neurogenic bladder, Lower gastrointestinal as constipation, soiling or incontinence. In this work we study the outcomes of fecal continence through a questionnaire and its effect on the quality of life of the affected children.


Eligibility criteria: Inclusion Criteria:

* all patients with sacrococcygeal teratoma operated after july 2010 and older than 3 years old.

Exclusion Criteria:

* Patients lost to follow up before 6 months after surgery.
* Patients with Currarino triad.

Primary outcomes:
measure: Fecal continence
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospitals
Study officials:
References: